Alliance Health Project
San Francisco, California, 94102, United States
NCT Number: NCT01926184
In the era of HIV treatment as prevention (TasP), efforts are needed to identify evidence-based combination prevention approaches that achieve greater decreases HIV viral load among populations that are more likely to engage in HIV transmission risk behavior. Because methamphetamine-using men who have sex with men (MSM) are at greater risk for acquiring and transmitting HIV, interventions targeting stimulant use in this population of high-risk men could boost the effectiveness of TasP. At present, only conditional cash transfer approaches such as contingency management (CM) have demonstrated short- term efficacy in reducing stimulant use among substance-using MSM who are not actively seeking formal treatment. The proposed RCT will examine the efficacy of a positive affect intervention that is designed to optimize the effectiveness of CM to achieve long-term reductions in stimulant use and HIV viral load in this population. the team will examine the efficacy of this integrative intervention in a randomized controlled trial (RCT) with 110 HIV-positive, methamphetamine-using MSM. After enrolling in CM, participants will be randomized to receive either: 1) the positive affect intervention; or 2) a attention-matched control condition. Follow-up data will be collected at 3, 6, 12, and 15 months post-randomization. This RCT will provide an opportunity to examine the efficacy of an integrative intervention designed to promote long-term reductions in HIV viral load as the primary outcome. Secondary outcomes that will be examined include: increases positive affect, reductions in stimulant use, improvements in T-helper (CD4+) count, unsuppressed viral load, and decreases HIV transmission risk behavior. Identifying an efficacious intervention approach to decrease HIV viral load among methamphetamine-using MSM would substantially support the goals of the National HIV/AIDS Strategy to reduce HIV incidence and mitigate HIV-related health disparities.
Looking for future studies?
Notify Me18 year and older
Male
Interventional
Not applicable
San Francisco, California, 94102, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
Other names: Positive Reinforcement Opportunity Project (PROP)
Time frame: 15 Months
Log10 HIV viral load change and log10 viral load at 15 months
Time frame: 15 Months
Any unsuppressed viral load (>= 200 copies/mL) over the 15-month follow-up period.
Time frame: 15 Months
Change in T-helper (CD4+) count
Time frame: 15 Months
Changes in methamphetamine and cocaine use (assessed via self-report and urine toxicology screening) over the 15-month follow-up.
Time frame: 15 Months
Changes in positive affect, negative affect, and depressive symptoms over the 15-month follow-up.
Time frame: 15 Months
Changes in self-reported HIV transmission risk behavior with an unsuppressed HIV viral load (>= 200 copies/mL) over the 15-month follow-up.
University of California, San Francisco
Other
Randomized Controlled Trial of an Integrative Intervention for Non-Treatment-Seeking Meth Users
Acronym: ARTEMIS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04194021
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Yaoundé, Centre Region, Cameroon
View Trial DetailsNCT04357821
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
San Francisco, California, United States
View Trial DetailsNCT03730987
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Miami, Florida, United States
View Trial DetailsNCT05609513
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Kampala, Uganda
View Trial Details